Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fourteen-day quadruple therapy vs seven-day sequential quadruple therapies for Helicobacter pylori eradication
IRCT201708071155N26Phase 3Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Jul 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of bismuth subcitrate, pantoprazole, amoxicillin, clarithromycin, metronidazole and 1 more in Helicobacter pylori infection (3 arms), sponsored by Guilan University of Medical Sciences. Primary endpoint: Helicobacter pylori eradication rate. Started Jul 2017; status: completed.
02
Drugs
bismuth subcitratepantoprazoleamoxicillinclarithromycinmetronidazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT201708071155N26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201708071155N26.